

**SYNTHESIS OF CARBOXAMIDOSTILBENE
ANALOGUES VIA HECK-CROSS COUPLING
REACTION, *IN SILICO* AND ANTIDIABETES
EVALUATION**

MAHDI BABAI

UNIVERSITI SAINS MALAYSIA

2025

**SYNTHESIS OF CARBOXAMIDOSTILBENE
ANALOGUES VIA HECK-CROSS COUPLING
REACTION, *IN SILICO* AND ANTIDIABETES
EVALUATION**

by

MAHDI BABAI

**Thesis submitted in fulfilment of the requirements
for the degree of
Doctor of Philosophy**

February 2025

ACKNOWLEDGEMENT

First and foremost, I would like to express my deepest gratitude to Allah, the Exalted, for the opportunity and infinite help in reaching another milestone in my academic career. My deepest appreciation and gratitude goes to Dr Mohamad Nurul Azmi bin Mohamad Taib, my supervisor and mentor, whose expertise, understanding and patience have greatly enriched my study experience. I appreciate your extensive knowledge and skills in many areas, your guidance and immense support throughout this journey. Your encouragement and insightful feedback have been invaluable.

I must express my deep gratitude to my co-supervisors, Dr Mohamad Hafizi Abu Bakar and Prof. Dato' Dr. Hasnah Osman, for their help, guidance and encouragement. Their time, efforts and understanding, coupled with their great wisdom and wealth of experience, have inspired me throughout my studies. Special thanks goes to my colleagues and friends at Universiti Sains Malaysia for providing me with a stimulating and enjoyable environment in which to learn and grow. I am especially grateful to Mohammad Tahir, Mohammad Idris, Ibrahim Dankane Bafarawa, Muhammad Solehin Abd Ghani, Mahmoud Abushattal, Sadiq Abubakar and Nurain Syazwani Mohd Zaki for their support during my research. I would like to thank all members of the Natural Products and Organic Synthesis Laboratory, as well as the staff and students of the School of Chemical Sciences, for their generosity and encouragement. The entire time I spent studying and living in Penang, Malaysia was truly memorable and rewarding. Finally, I would like to thank my father, Mohammad Mahdi and my mother, Khadija Mohammad Mahdi; my wife, Rukayya Umar; and my children Aliyu Idris Mahdi, Asma'u I. Mahdi, Fatima I. Mahdi, Khadija I. Mahdi and Mohammad I. Mahdi. My appreciation and gratitude also goes to my brothers and sisters for their encouragement

and prayers. Without their unwavering support over the past few years, it would have been impossible to complete my studies.

TABLE OF CONTENTS

ACKNOWLEDGEMENT	ii
TABLE OF CONTENTS	iv
LIST OF TABLES.....	xii
LIST OF SCHEMES.....	xvii
LIST OF SYMBOLS.....	xix
LIST OF ABBREVIATIONS.....	xxi
LIST OF APPENDICES	xxv
ABSTRAK.....	xxxii
ABSTRACT	xxxiv
CHAPTER 1 INTRODUCTION	1
1.1 Background of the study	1
1.2 Problem statement	6
1.3 Research objectives	7
1.4 Scope of research.....	8
CHAPTER 2 LITERATURE REVIEW	9
2.1 Stilbene and its derivatives	9
2.2 Synthesis of stilbene and its derivatives	11
2.2.1 Palladium catalysed synthesis of stilbenes	11
2.2.1(a) Heck coupling reaction	11
2.2.1(b) Stille coupling reaction	21
2.2.1(c) Suzuki coupling reaction.....	22
2.2.1(d) Sonogashira reaction	24
2.2.2 Non-metal catalysed synthesis of stilbenes	25
2.2.2(a) Aldol-type condensation reaction	26
2.2.2(b) Wittig reaction.....	27

2.2.2(c)	Horner-Wadsworth-Emmons (HWE)	31
2.2.2(d)	Julia olefination reaction	36
2.2.2(e)	The Perkin reaction	38
2.3	Biological activities of stilbenes	39
2.4	Role of stilbenes as inhibitors of diabetic enzymes	46
2.5	Overview of diabetes and microvascular complications	47
2.5.1	Diabetic nephropathy	50
2.5.2	Diabetic retinopathy	50
2.5.3	Diabetic neuropathy	50
2.6	Targeted proteins for diabetes treatment	51
2.6.1	11 β -hydroxysteroid dehydrogenase (HSD)	51
2.6.2	Glutamine fructose-6-phosphate amidotransferase (GFAT or GFPT)	52
2.6.3	α -Amylase (α -Amy)	53
2.6.4	α -Glucosidase (α -Gls)	53
2.7	Important amino acids	53
2.8	<i>In silico</i> studies	55
2.8.1	Drug-likeness	56
2.8.2	Molecular docking	57
2.8.3	Database for receptor and ligand	58
2.8.4	Docking software	61
CHAPTER 3 METHODOLOGY		62
3.1	Chemicals and solvents used in the synthesis	62
3.2	General experimental methods and instrumentation	63
3.2.1	Melting point measurement	63
3.2.2	Thin layer chromatography (TLC)	64
3.2.3	Fourier transform infrared spectroscopy spectral analysis	65
3.2.4	Nuclear magnetic resonance	65

3.2.6	HRESIMS analysis	65
3.3	Synthesis and characterisation	66
3.3.1	General procedure for the preparation of styrenes 183	66
3.3.1(a)	3,4,5-trimethoxystyrene (183a).....	66
3.3.1(b)	2,4-dimethoxystyrene (183b).....	67
3.3.1(c)	2,5-dimethoxystyrene (183c)	68
3.3.2	Synthesis of <i>ortho</i> -carboxamidostilbenes.....	68
3.3.2(a)	General procedure for the preparation of acylamides, 185a-185f	69
3.3.2(a)(i)	<i>N</i> -(2-iodophenyl)acetamide (185a).....	69
3.3.2(a)(ii)	<i>N</i> -(2-iodophenyl)butyramide (185b)	70
3.3.2(a)(iii)	<i>N</i> -(2-iodophenyl)isobutyramide (185c)	71
3.3.2(a)(iv)	<i>N</i> -(2-iodophenyl)furan-2- carboxamide (185d)	71
3.3.2(a)(v)	<i>N</i> -(2- iodophenyl)cyclohexanecarboxamide (185e)	72
3.3.2(a)(vi)	<i>N</i> -(2-iodophenyl)benzamide (185f)	72
3.3.2(b)	General procedure for the preparation of <i>ortho</i> - carboxamidostilbenes 186-188	73
3.3.2(b)(i)	(<i>E</i>)- <i>N</i> -(2-(3,4,5- trimethoxystyryl)phenyl)acetamide (186a).....	74
3.3.2(b)(ii)	(<i>E</i>)- <i>N</i> -(2'-(3,4,5- trimethoxystyryl)phenyl)butyramide (186b).....	74
3.3.2(b)(iii)	(<i>E</i>)- <i>N</i> -(2'-(3,4,5- trimethoxystyryl)phenyl)isobutyramid e (186c)	75
3.3.2(b)(iv)	(<i>E</i>)- <i>N</i> -(2'-(3,4,5- trimethoxystyryl)phenyl)furan-2- carboxamide (186d).....	76

3.3.2(b)(v)	(<i>E</i>)- <i>N</i> -(2'-(3,4,5-trimethoxystyryl)phenyl)cyclohexane carboxamide (186e)	77
3.3.2(b)(vi)	(<i>E</i>)- <i>N</i> -(2'-(3,4,5-trimethoxystyryl)phenyl)benzamide (186f).....	78
3.3.2(c)(i)	(<i>E</i>)- <i>N</i> -(2'-(2,4-dimethoxystyryl)phenyl)acetamide (187a).....	78
3.3.2(c)(ii)	(<i>E</i>)- <i>N</i> -(2'-(2,4-dimethoxystyryl)phenyl)butyramide (187b).....	79
3.3.2(c)(iii)	(<i>E</i>)- <i>N</i> -(2'-(2,4-dimethoxystyryl)phenyl)isobutyramide (187c)	80
3.3.2(c)(iv)	(<i>E</i>)- <i>N</i> -(2'-(2,4-dimethoxystyryl)phenyl)furan-2-carboxamide (187d)	81
3.3.2(c)(v)	(<i>E</i>)- <i>N</i> -(2'-(2,4-dimethoxystyryl)phenyl)cyclohexane carboxamide (187e)	82
3.3.2(c)(vi)	(<i>E</i>)- <i>N</i> -(2'-(2,4-dimethoxystyryl)phenyl)benzamide (187f).....	83
3.3.2(d)(i)	(<i>E</i>)- <i>N</i> -(2'-(2,5-dimethoxystyryl)phenyl)acetamide (188a).....	84
3.3.2(d)(ii)	(<i>E</i>)- <i>N</i> -(2'-(2,5-dimethoxystyryl)phenyl)butyramide (188b).....	84
3.3.2(d)(iii)	(<i>E</i>)- <i>N</i> -(2'-(2,5-dimethoxystyryl)phenyl)isobutyramide (188c)	85
3.3.2(d)(iv)	(<i>E</i>)- <i>N</i> -(2'-(2,5-dimethoxystyryl)phenyl)furan-2-carboxamide (188d)	86
3.3.2(d)(v)	(<i>E</i>)- <i>N</i> -(2'-(2,5-dimethoxystyryl)phenyl)cyclohexane carboxamide (188e)	87

	3.3.2(d)(vi)	(<i>E</i>)- <i>N</i> -(2'-(2,5-dimethoxystyryl)phenyl)benzamide (188f).....	88
3.3.3	Synthesis of <i>para</i> -carboxamidostilbene		88
	3.3.3(a)	General procedure for the preparation of acylamide (190a-190f)	89
	3.3.3(a)(i)	<i>N</i> -(4-iodophenyl)acetamide (190a).....	89
	3.3.3(a)(ii)	<i>N</i> -(4-iodophenyl)butyramide (190b)	90
	3.3.3(a)(iii)	<i>N</i> -(4-iodophenyl)isobutyramide (190c)	91
	3.3.3(a)(iv)	<i>N</i> -(4-iodophenyl)furan-2'-carboxamide (190d)	91
	3.3.3(a)(v)	<i>N</i> -(4-iodophenyl)cyclohexanecarboxamide (190e)	92
	3.3.3(a)(vi)	<i>N</i> -(4-iodophenyl)benzamide (190f)	92
	3.3.3(b)	General procedure for the preparation of <i>para</i> -carboxamidostilbenes 191-193	93
	3.3.3(b)(i)	(<i>E</i>)- <i>N</i> -(4'-(2,4-dimethoxystyryl)phenyl)acetamide (191a).....	93
	3.3.3(b)(ii)	(<i>E</i>)- <i>N</i> -(4'-(2,4-dimethoxystyryl)phenyl)butyramide (191b).....	94
	3.3.3(b)(iii)	(<i>E</i>)- <i>N</i> -(4'-(2,4-dimethoxystyryl)phenyl)isobutyramide (191c)	95
	3.3.3(b)(iv)	(<i>E</i>)- <i>N</i> -(4'-(2,4-dimethoxystyryl)phenyl)furan-2-carboxamide (191d)	96
	3.3.3(b)(v)	(<i>E</i>)- <i>N</i> -(4'-(2,4-dimethoxystyryl)phenyl)cyclohexanecarboxamide (191e)	97
	3.3.3(b)(vi)	(<i>E</i>)- <i>N</i> -(4'-(2,4-dimethoxystyryl)phenyl)benzamide (191f).....	98

3.3.3(c)(i)	(<i>E</i>)- <i>N</i> -(4'-(2,5-dimethoxystyryl)phenyl)acetamide (192a).....	98
3.3.3(c)(ii)	(<i>E</i>)- <i>N</i> -(4'-(2,5-dimethoxystyryl)phenyl)butyramide (192b).....	99
3.3.3(c)(iii)	(<i>E</i>)- <i>N</i> -(4'-(2,5-dimethoxystyryl)phenyl)isobutyramide (192c).....	100
3.3.3(c)(iv)	(<i>E</i>)- <i>N</i> -(4'-(2,5-dimethoxystyryl)phenyl)furan-2-carboxamide (192d).....	101
3.3.3(c)(v)	(<i>E</i>)- <i>N</i> -(4'-(2,5-dimethoxystyryl)phenyl)cyclohexane carboxamide (192e).....	102
3.3.3(c)(vi)	(<i>E</i>)- <i>N</i> -(4'-(2,5-dimethoxystyryl)phenyl)benzamide (192f).....	103
3.4	α -Amylase inhibition evaluation	103
3.4.1	Assay for α -amylase inhibition.....	103
3.4.2	Statistical analysis.....	105
3.5	<i>In silico</i> studies	105
3.5.1	Drug-likeness and pharmacokinetics studies.....	105
3.5.2	Molecular docking.....	105
3.5.2(a)	Software and hardware/bioinformatics tool used in molecular docking.....	106
3.5.2(b)	Ligand preparation	106
3.5.2(c)	Receptor preparation	107
3.5.2(d)	Protein-ligand preparation.....	108
3.5.2(e)	Molecular docking analysis and data interpretation	111
3.5.2(f)	Validation of docking parameters	112
CHAPTER 4 RESULTS AND DISCUSSIONS.....		113
4.1	Overview.....	113

4.2	Chemistry.....	113
4.2.1	Structure elucidation of styrene.....	113
	4.2.1(a) 3,4,5-trimethoxystyrene (183a).....	114
4.3	Synthesis of <i>ortho</i> -carboxamidostilbenes.....	117
4.3.1	Structure elucidation of <i>N</i> -(2-iodophenyl)acylamides 185 (a-f) ..	117
	4.3.1(a) <i>N</i> -(2-iodophenyl)butyramide (185b).....	118
4.3.2	Structure elucidation of <i>ortho</i> -carboxamidostilbenes, 186-188 ...	122
	4.3.2(a) (<i>E</i>)- <i>N</i> -(2'-(3,4,5-trimethoxystyryl)phenyl)benzamide (186f).....	122
4.4	Synthesis of <i>para</i> -carboxamidostilbenes, 191-192	129
4.4.1	Structure elucidation of <i>N</i> -(4-iodophenyl)acylamides (190).....	129
	4.4.1(a) <i>N</i> -(4-iodophenyl)isobutyramide (190c)	130
4.4.2	Structure elucidation of <i>para</i> -carboxamidostilbenes, 191-192	134
	4.4.2(a) (<i>E</i>)- <i>N</i> -(4'-(2,4-dimethoxystyryl)phenyl)furan-2- carboxamide (191d)	134
4.5	Mechanistic interpretation of Heck coupling reaction.....	140
4.6	Antidiabetic studies	141
4.6.1	α -Amylase inhibitory assays.....	141
4.6.2	Structure-Activity Relationship (SAR) Analysis of <i>Ortho</i> - Carboxamidostilbene Derivatives.....	145
4.7	<i>In silico</i> study.....	149
4.7.1	Drug-likeness and ADME studies	149
4.7.2	Molecular docking	157
	4.7.2(a) Docking simulations of <i>ortho</i> -carboxamidostilbene derivatives for the evaluation of their potential as α - amylase inhibitors	158
	4.7.2(b) Docking simulations of <i>para</i> -carboxamidostilbene derivatives to evaluate their potential as α -amylase inhibitors	162

CHAPTER 5	CONCLUSION AND FUTURE RECOMMENDATIONS ...	169
5.1	Conclusion	169
5.2	Recommendations for future research	172
REFERENCES	174
APPENDICES		
LIST OF PUBLICATIONS		

LIST OF TABLES

	Page
Table 3.1	Melting points and percentage yield of compounds 186-188 and 191-192 63
Table 3.2	Retention factor (R_f) of prepared compounds 186-188 and 191-192 64
Table 3.3	2D and 3D structures of selected compounds for protein-ligand docking 109
Table 4.1	The physical properties of <i>N</i> -(2-iodophenyl)acylamides, 185a–185f 118
Table 4.2	Physical properties of <i>N</i> -(4-iodophenyl)acylamides 190a–190f 130
Table 4.3	α -Amylase inhibitory activity of <i>ortho</i> -carboxamidostilbenes 186-188 142
Table 4.4	α -Amylase inhibitory activity of <i>para</i> -carboxamidostilbenes 191–192 144
Table 4.5	Physicochemical properties, lipophilicity and drug-likeness of 186-188 151
Table 4.6	The interaction between synthesised compounds and cytochrome P450 isoforms prediction using SwissADME..... 152
Table 4.7	Prediction of physicochemical properties for compounds 191-192 156
Table 4.8	The interaction of synthesised compounds with cytochromes P450 isoforms predicted using SwissADME 157
Table 4.9	<i>In silico</i> binding energy between <i>ortho</i> -carboxamidostilbenes with α -amylase..... 159
Table 4.10	Docking interactions of synthesised compounds within the binding pocket of α -amylase..... 161
Table 4.11	<i>In silico</i> binding energy between <i>para</i> -carboxamidostilbenes with 165

Table 4.12	Docking interactions of synthesised compounds within the binding pocket of α -amylase.....	165
------------	---	-----

LIST OF FIGURES

	Page
Figure 1.1	Structure of <i>trans</i> - and <i>cis</i> -stilbenes 2
Figure 1.2	Structures of substituted and resveratrol 3
Figure 1.3	Chemical structures of various (<i>E</i>)-stilbene derivatives..... 3
Figure 1.4	Chemical structures of <i>trans</i> -3,5-dimethoxy-4-hydroxytoluene and <i>trans</i> -3,3,4,5-tetrahydroxystilbene 4
Figure 1.5	Chemical structures of notable polyphenolic compounds..... 4
Figure 1.6	Diabetes around the world in 2021 7
Figure 2.1	Structures of methoxylated stilbene derivatives..... 10
Figure 2.2	Some biologically active stilbene 40
Figure 2.3	Structure of oxyresveratrol 42
Figure 2.4	Structure of piceatannol..... 43
Figure 2.5	Structure of (<i>E</i>)- <i>N</i> -(2-(3'-fluorostyryl)phenyl)acetamide (175) 44
Figure 2.6	Structure of (<i>Z</i>)-3-(2'-chloro-5'-(trifluoromethyl)phenyl)-2-(4- methoxyphenyl)acrylic acid (176)..... 44
Figure 2.7	Structure of (<i>E</i>)-3-(4-chlorophenyl)- <i>N</i> '-methyl-2- phenylacrylohydrazide 45
Figure 2.8	Structure of (<i>E</i>)-1,3-dimethoxy-5-(4'-methoxystyryl)benzene 45
Figure 2.9	Interconversion of cortisone and cortisol mediated by 11 β -HSD1 and 11 β -HSD1 52
Figure 2.10	Structure of Isorhapontigenin (ISO)..... 57
Figure 2.11	The 2QV4 data page of RCSB PDB database (https://www.rcsb.org/)..... 60
Figure 2.12	3D ligand saved as PDB in Chem3D XML..... 61
Figure 3.1	3D structure of compound 186f in Chem3D XML 107
Figure 3.2	2QV4 protein after removal of all nonstandard molecules 108

Figure 4.1	Preparation of 3,4,5-trimethoxystyrene (183a)	114
Figure 4.2	FTIR spectrum of compound 183a	116
Figure 4.3	¹ H NMR spectrum (500 MHz, CDCl ₃) of compound 183a	116
Figure 4.4	Dept 135 (a) and ¹³ C-NMR (b) (125 MHz, CDCl ₃) spectrum of compound 183a	117
Figure 4.5	FTIR spectrum of compound 185b	120
Figure 4.6	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 185b	121
Figure 4.7	¹³ C-NMR (125 MHz, CDCl ₃) spectrum of compound 185b	121
Figure 4.8	¹ H- ¹ H COSY correlation of compound 186f	125
Figure 4.9	HMBC (¹ H → ¹³ C) correlations of compound 186f	125
Figure 4.10	HRESIMS (+ESI) [M+Na] ⁺ of compound 186f	126
Figure 4.11	FTIR spectrum of compound 186f	126
Figure 4.12	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 186f	127
Figure 4.13	¹³ C NMR (125MHz, CDCl ₃) spectrum of compound 186f	127
Figure 4.14	¹ H- ¹ H COSY spectrum of compound 186f	128
Figure 4.15	¹ H- ¹³ C HMBC spectrum of compound 186f	128
Figure 4.16	FTIR spectrum of compound 190c	132
Figure 4.17	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 190c	133
Figure 4.18	¹³ C NMR (125 MHz, CDCl ₃) spectrum of compound 190c	133
Figure 4.19	Key ¹ H- ¹ H COSY and HMBC correlations of compound 191d	137
Figure 4.20	HRESIMS (+ESI) [M+Na] ⁺ of compound 191d	137
Figure 4.21	FTIR spectrum of compound 191d	138
Figure 4.22	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 191d	138
Figure 4.23	¹³ C-NMR (125 MHz, CDCl ₃) of compound 191d	139
Figure 4.24	¹ H- ¹ H COSY spectrum of compound 191d	139
Figure 4.25	¹ H- ¹³ C HMBC spectrum of compound 191d	140

Figure 4.26	Structures of the most potent <i>ortho</i> -carboxamidostilbenes	143
Figure 4.27	Structures of the most potent <i>para</i> -carboxamidostilbenes	145
Figure 4.28	A designed strategy for the SAR studies of <i>ortho</i> -carboxamidostilbene derivatives	147
Figure 4.29	A designed strategy for the SAR studies of <i>ortho</i> -carboxamidostilbene derivatives	149
Figure 4.30	Structures of the most active <i>ortho</i> -carboxamidostilbenes	159
Figure 4.31	3D binding modes of compounds 186e (A), 186f (B), 187e (C) and 188b (D) within the active site of α -amylase. Dotted lines are showing specific interaction between ligand and receptor protein .	162
Figure 4.32	3D binding modes of compounds 191d (A), 191e (B), and 191f (C) within the active site of α -amylase. Dotted lines are showing specific interaction between ligand and receptor protein	167
Figure 4.33	3D binding modes of compound 192c (D), 192d (E), 192e (F) and 192f (G) within the active site of α -amylase. Dotted lines are showing specific interaction between ligand and receptor protein .	168
Figure 5.1	Structures of the most potent <i>ortho</i> -carboxamidostilbenes	171
Figure 5.2	Structures of the most potent <i>para</i> -carboxamidostilbenes	172

LIST OF SCHEMES

	Page
Scheme 2.1 Schematic palladium catalysed synthesis of stilbene	12
Scheme 2.2 Mizoroki-Heck reaction of aryl halides with olefins catalysed by PVP-Pd NPs.....	13
Scheme 2.3 Synthesis of nitrovinyl stilbene	14
Scheme 2.4 Base-free Mizoroki-Heck cross-coupling for the synthesis of substituted stilbene	15
Scheme 2.5 A recent one-pot synthesis of stilbene using Heck reaction with solvent modification	15
Scheme 2.6 Synthesis of stilbene scaffold	16
Scheme 2.7 Heck reaction of <i>N</i> -(2-iodophenyl)acylamide using styrene.....	16
Scheme 2.8 Decarbonylative Heck reaction	17
Scheme 2.9 Dehydration Heck arylation of benzylic alcohol 55 with aryl bromides	18
Scheme 2.10 Synthesis of Gaylussacin (61a) and its derivative (61b).....	19
Scheme 2.11 Synthesis of amido1,3-diarylpropene compounds	20
Scheme 2.12 Synthesis of stilbene utilising TAAILs in the Mizoroki-Heck reaction	21
Scheme 2.13 Synthesis of substituted stilbene via Stille coupling	22
Scheme 2.14 The Suzuki cross-coupling synthesis of stilbene scaffold.....	23
Scheme 2.15 Synthesis of stilbene derivatives via Suzuki coupling	24
Scheme 2.16 Synthesis of stilbene derivatives	24
Scheme 2.17 Synthesis of resveratrol via Sonogashira reaction.....	25
Scheme 2.18 Synthesis of resveratrol via Aldol-type condensation	27
Scheme 2.19 The resonance structure of trimethylphosphonium methylide	27

Scheme 2.20	Synthesis of trimethyl phosphonium ylide	28
Scheme 2.21	Synthesis of resveratrol via Wittig reaction	29
Scheme 2.22	Synthesis of pinacolyl boronate stilbene	30
Scheme 2.23	Synthetic of pterostilbene (10)	31
Scheme 2.24	General synthetic route for the synthesis of the <i>trans</i> -methylthiostilbene analogues	32
Scheme 2.25	Synthesis of benzoselenazole-stilbene	33
Scheme 2.26	Synthetic pathway of prenylated stilbenoids methyl ester	34
Scheme 2.27	Reaction pathway of 4-bromomethylbenzocoumarin derivatives	35
Scheme 2.28	Synthetic route for the target molecule	36
Scheme 2.29	The Julia olefination reaction	37
Scheme 2.30	Synthesis of stilbene hydrazine	38
Scheme 2.31	Synthesis of <i>trans</i> -resveratrol by Parkin reaction	39
Scheme 2.32	Synthesis of methoxylated <i>trans</i> -stilbene.....	46
Scheme 3.1	Preparation of styrene via Wittig reaction.....	66
Scheme 3.2	Synthesis of <i>ortho</i> -carboxamido stilbenes via the Heck coupling	69
Scheme 3.3	Synthesis of <i>para</i> -carboxamido stilbenes via the Heck coupling	90
Scheme 4.1	Synthetic route towards the preparation of <i>N</i> -(2-iodophenyl)acylamides.....	119
Scheme 4.2	Synthesis of <i>ortho</i> -carboxamidostilbene (186f).....	123
Scheme 4.3	Synthetic pathway for preparing of <i>N</i> -(4-iodophenyl) acylamides .	130
Scheme 4.4	Synthesis of <i>para</i> -carboxamidostilbene	135
Scheme 4.5	Mechanistic pathway of Heck coupling	142

LIST OF SYMBOLS

α	Alpha
β	Beta
δ	Chemical shift
λ_{\max}	Maximum wavelength
nm	Nanometer
mL	Millimolar
mg/mL	Milligram per Milliliter
$\mu\text{g/mL}$	Microgram per Milliliter
μM	Micromolar
$^{\circ}\text{C}$	Degree Celsius
\AA	Angstrom
J	Coupling constant
s	Singlet
d	Doublet
dd	Doublet of doublets
dt	Doublet of triplets
t	Triplet
Hz	Hertz
g mol^{-1}	Gram per mol
g	Gram
M	Molar
mg	Milligram
MHz	Mega Hertz
cm	Centimeter
cm^{-1}	Per centimeter

δ_C	Chemical shift carbon
δ_H	Chemical shift proton
nM	Nano molar
<i>o</i> -	<i>Ortho</i>
<i>p</i> -	<i>Para</i>
ppm	Parts per million
ppb	Parts per billion
%	Percentage
% T	Percentage transmittance
% Yield	Percentage yield
^1H	Proton
R	Substituent group

LIST OF ABBREVIATIONS

ADME	Adsorption, distribution, metabolism, and Excretion
ATR	Attenuated Total Reflectance
BBB	Blood-Brain Barrier
b. p.	Boiling Point
cat	Catalyst
CC	Column chromatography
CDCl ₃	Deuterated chloroform
CH	Methine
CH ₂	Methylene
CH ₃	Methyl
CHCl ₃	Trichloromethane
COSY	Correlation Spectroscopy
CVC	Cardiovascular disease
CYP1A2	Cytochrome P450 family 1 subfamily A member 2
CYP2C19	Cytochrome P450 family 2 subfamily C member 19
CYP2C9	Cytochrome P450 family 2 subfamily C member 9
CYP3A4	Cytochrome P450 family 3 subfamily A member 4
DEPT	Distortionless Enhancement by Polarization Transfer
DMF	Dimethyl formamide
DMSO	Dimethyl sulfoxide
DNA	Deoxyribonucleic acid
DNS	Dinitrosalicylic acid
DMU-212	<i>trans</i> -3,4,5,4'-tetramethoxystilbene

Equiv	Equivalent
Et ₃ N	Triethylamine
EtOAc	Ethyl acetate
FTIR	Fourier transform infrared
F6P	Fructose-6-phosphate
GFAT	Glutamine fructose-6-phosphate amidotransferase
GlcN6P	Glucosamine-6-phosphate
GIA	Gastrointestinal absorption
HDL	High Density lipoprotein
HMBC	Heteronuclear Multiple Bond Correlation
HSD	11 β -hydroxysteroid dehydrogenase
HSQC	Heteronuclear Single Quantum Correlation
HRMS	High resolution mass spectrometry
IC ₅₀	Inhibition concentration at 50%
IL-1 β	Interleukin 1 beta
IR	Infrared
KOH	Potassium hydroxide
LDL	Low Density lipoprotein
Log P	Logarithm of partition coefficient of compound between n-octane and water
MeCN	Methyl cyanide
MeOH	Methanol
m. p.	Melting point
MR	Molar Refractivity
MW	Molecular weight

NADP	Nicotinamide adenine dinucleotide phosphate
NADPH	Nicotinamide adenine dinucleotide phosphate oxidase
NH ₄ Cl	Ammonium chloride
Na ₂ CO ₃	Sodium carbonate
NMR	Nuclear magnetic resonance
nHBD	Number of Hydrogen bond donor
nHBA	Number of Hydrogen bond acceptor
nrot B	Number of rotatable bonds
OCH ₃	Methoxy
OH	Hydroxyl
PDB	Protein data bank
Pd(OAc) ₂	Palladium(II) acetate
Ph	Phenyl
Rf	Retention factor/ Retardation factor
RNA	Ribonucleic acid
RNS	Reactive nitrogen species
ROS	Reactive oxygen specie
RVS	Resveratrol
s	singlet
SAR	Structure-activity relationship
SDR	Short-chain dehydrogenase/reductase
TEA	triethylamine
THF	Tetrahydrofuran
TLC	Thin layer chromatography
TMS	Tetramethyl silane

TNF- α	Tumor Necrosis Factor Alpha
TOF	Time of flight
TSPA	Topological polar surface area
UV	Ultraviolet
UDP-GlcNAc	Uridine diphosphate <i>N</i> -acetylglucosamine

LIST OF APPENDICES

Appendix A1	FTIR spectrum of compound 183a
Appendix A2	^1H NMR (500 MHz, CDCl_3) spectrum of compound 183a
Appendix A3	^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 183a
Appendix A4	FTIR spectrum of compound 183b
Appendix A5	^1H NMR (500 MHz, CDCl_3) spectrum of compound 183b
Appendix A6	^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 183b
Appendix A7	FTIR spectrum of compound 183c
Appendix A8	^1H NMR (500 MHz, CDCl_3) spectrum of compound 183c
Appendix A9	^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 183c
Appendix A10	FTIR spectrum of compound 185a
Appendix A11	^1H NMR (500 MHz, CDCl_3) spectrum of compound 185a
Appendix A12	^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 185a
Appendix A13	FTIR spectrum of compound 185b
Appendix A14	^1H NMR (500 MHz, CDCl_3) spectrum of compound 185b
Appendix A15	^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 185b
Appendix A16	FTIR spectrum of compound 185c
Appendix A17	^1H NMR (500 MHz, CDCl_3) spectrum of compound 185c
Appendix A18	^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 185c
Appendix A19	FTIR spectrum of compound 185d
Appendix A20	^1H NMR (500 MHz, CDCl_3) spectrum of compound 185d
Appendix A21	^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 185d
Appendix A22	FTIR spectrum of compound 185e
Appendix A23	^1H NMR (500 MHz, CDCl_3) spectrum of compound 185e
Appendix A24	^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 185e

Appendix A25	FTIR spectrum of compound 185f
Appendix A26	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 185f
Appendix A27	¹³ C-NMR (125 MHz, CDCl ₃) spectrum of compound 185f
Appendix A28	HRESIMS (+ESI) [M+Na] ⁺ for compound 186a
Appendix A29	FTIR spectrum of compound 186a
Appendix A30	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 186a
Appendix A31	¹³ C-NMR (125 MHz, CDCl ₃) spectrum of compound 186a
Appendix A32	HRESIMS (+ESI) [M+Na] ⁺ for compound 186b
Appendix A33	FTIR spectrum of compound 186b
Appendix A34	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 186b
Appendix A35	¹³ C NMR (125 MHz, CDCl ₃) spectrum of compound 186b
Appendix A36	HRESIMS (+ESI) [M+Na] ⁺ for Compound 186c
Appendix A37	FTIR spectrum of compound 186c
Appendix A38	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 186c
Appendix A39	¹³ C NMR (125 MHz, CDCl ₃) spectrum of compound 186c
Appendix A40	HRESIMS (+ESI) [M+Na] ⁺ for Compound 186d
Appendix A41	FTIR spectrum of compound 186d
Appendix A42	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 186d
Appendix A43	¹³ C NMR (125 MHz, CDCl ₃) spectrum of compound 186d
Appendix A44	HRESIMS (+ESI) [M+Na] ⁺ for Compound 186e
Appendix A45	FTIR spectrum of compound 186e
Appendix A46	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 186e
Appendix A47	¹³ C NMR (125 MHz, CDCl ₃) spectrum of compound 186e
Appendix A48	HRESIMS (+ESI) [M+Na] ⁺ for Compound 186f
Appendix A49	FTIR spectrum of compound 186f
Appendix A50	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 186f
Appendix A51	¹³ C NMR (125 MHz, CDCl ₃) spectrum of compound 186f

Appendix A52	HRESIMS (+ESI) [M+Na] ⁺ for Compound 187a
Appendix A53	FTIR spectrum of compound 187a
Appendix A54	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 187a
Appendix A55	¹³ C NMR (125 MHz, CDCl ₃) spectrum of compound 187a
Appendix A56	HRESIMS (+ESI) [M+Na] ⁺ for Compound 187b
Appendix A57	FTIR spectrum of compound 187b
Appendix A58	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 187b
Appendix A59	¹³ C NMR (125 MHz, CDCl ₃) spectrum of compound 187b
Appendix A60	HRESIMS (+ESI) [M+Na] ⁺ for Compound 187c
Appendix A61	FTIR spectrum of compound 187c
Appendix A62	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 187c
Appendix A63	¹³ C NMR (125 MHz, CDCl ₃) spectrum of compound 187c
Appendix A64	HRESIMS (+ESI) [M+Na] ⁺ for Compound 187d
Appendix A65	FTIR spectrum of compound 187d
Appendix A66	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 187d
Appendix A67	¹³ C NMR (125 MHz, CDCl ₃) spectrum of compound 187d
Appendix A68	HRESIMS (+ESI) [M+Na] ⁺ for Compound 187e
Appendix A69	FTIR spectrum of compound 187e
Appendix A70	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 187e
Appendix A71	¹³ C NMR (125 MHz, CDCl ₃) spectrum of compound 187e
Appendix A72	HRESIMS (+ESI) [M+Na] ⁺ for Compound 187f
Appendix A73	FTIR spectrum of compound 187f
Appendix A74	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 187f
Appendix A75	¹³ C NMR (125 MHz, CDCl ₃) spectrum of compound 187f
Appendix A76	HRESIMS (+ESI) [M+Na] ⁺ for Compound 188a
Appendix A77	FTIR spectrum of compound 188a
Appendix A78	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 188a

Appendix A79	^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 188a
Appendix A80	HRESIMS (+ESI) $[\text{M}+\text{Na}]^+$ for Compound 188b
Appendix A81	FTIR spectrum of compound 188b
Appendix A82	^1H NMR (500 MHz, CDCl_3) spectrum of compound 188b
Appendix A83	^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 188b
Appendix A84	HRESIMS (+ESI) $[\text{M}+\text{Na}]^+$ for Compound 188c
Appendix A85	FTIR spectrum of compound 188c
Appendix A86	^1H NMR (500 MHz, CDCl_3) spectrum of compound 188c
Appendix A87	^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 188c
Appendix A88	HRESIMS (+ESI) $[\text{M}+\text{Na}]^+$ for Compound 188d
Appendix A89	FTIR spectrum of compound 188d
Appendix A90	^1H NMR (500 MHz, CDCl_3) spectrum of compound 188d
Appendix A91	^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 188d
Appendix A92	HRESIMS (+ESI) $[\text{M}+\text{Na}]^+$ for Compound 188e
Appendix A93	FTIR spectrum of compound 188e
Appendix A94	^1H NMR (500 MHz, CDCl_3) spectrum of compound 188e
Appendix A95	^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 188e
Appendix A96	HRESIMS (+ESI) $[\text{M}+\text{Na}]^+$ for Compound 188f
Appendix A97	FTIR spectrum of compound 188f
Appendix A98	^1H NMR (500 MHz, CDCl_3) spectrum of compound 188f
Appendix A99	^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 188f
Appendix A100	FTIR spectrum of compound 190a
Appendix A101	^1H NMR (500 MHz, CDCl_3) spectrum of compound 190a
Appendix A102	^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 190a
Appendix A103	FTIR spectrum of compound 190b
Appendix A104	^1H NMR (500 MHz, CDCl_3) spectrum of compound 190b
Appendix A105	^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 190b

Appendix A106	FTIR spectrum of compound 190c
Appendix A107	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 190c
Appendix A108	¹³ C NMR (125 MHz, CDCl ₃) spectrum of compound 190c
Appendix A109	FTIR spectrum of compound 190d
Appendix A110	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 190d
Appendix A111	¹³ C NMR (125 MHz, CDCl ₃) spectrum of compound 190d
Appendix A112	FTIR spectrum of compound 190e
Appendix A113	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 190e
Appendix A114	¹³ C NMR (125 MHz, CDCl ₃) spectrum of compound 190e
Appendix A115	FTIR spectrum of compound 190f
Appendix A116	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 190f
Appendix A117	¹³ C NMR (125 MHz, CDCl ₃) spectrum of compound 190f
Appendix A118	HRMS (+ESI) [M+Na] ⁺ for Compound 191a
Appendix A119	FTIR spectrum of compound 191a
Appendix A120	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 191a
Appendix A121	¹³ C NMR (125 MHz, CDCl ₃) spectrum of compound 191a
Appendix A122	HRESIMS (+ESI) [M+Na] ⁺ for Compound 191b
Appendix A123	FTIR spectrum of compound 191b
Appendix A124	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 191b
Appendix A125	¹³ C NMR (125 MHz, CDCl ₃) spectrum of compound 191b
Appendix A126	HRESIMS (+ESI) [M+Na] ⁺ for Compound 191c
Appendix A127	FTIR spectrum of compound 191c
Appendix A128	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 191c
Appendix A129	¹³ C NMR (125 MHz, CDCl ₃) spectrum of compound 191c
Appendix A130	HRESIMS (+ESI) [M+Na] ⁺ for Compound 191d
Appendix A131	FTIR spectrum of compound 191d
Appendix A132	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 191d

Appendix A133	^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 191d
Appendix A134	HRESIMS (+ESI) $[\text{M}+\text{Na}]^+$ for Compound 191e
Appendix A135	FTIR spectrum of compound 191e
Appendix A136	^1H NMR (500 MHz, CDCl_3) spectrum of compound 191e
Appendix A137	^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 191e
Appendix A138	HRESIMS (+ESI) $[\text{M}+\text{Na}]^+$ for Compound 191f
Appendix A139	FTIR spectrum of compound 191f
Appendix A140	^1H NMR (500 MHz, CDCl_3) spectrum of compound 191f
Appendix A141	^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 191f
Appendix A142	HRESIMS (+ESI) $[\text{M}+\text{H}]^+$ for Compound 192a
Appendix A143	FTIR spectrum of compound 192a
Appendix A144	^1H NMR (500 MHz, CDCl_3) spectrum of compound 192a
Appendix A145	^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 192a
Appendix A146	HRESIMS (+ESI) $[\text{M}+\text{H}]^+$ for Compound 192b
Appendix A147	FTIR spectrum of compound 192b
Appendix A148	^1H NMR (500 MHz, CDCl_3) spectrum of compound 192b
Appendix A149	^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 192b
Appendix A150	HRESIMS (+ESI) $[\text{M}+\text{H}]^+$ for Compound 192c
Appendix A151	FTIR spectrum of compound 192c
Appendix A152	^1H NMR (500 MHz, CDCl_3) spectrum of compound 192c
Appendix A153	^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 192c
Appendix A154	HRESIMS (+ESI) $[\text{M}+\text{H}]^+$ for Compound 192d
Appendix A155	FTIR spectrum of compound 192d
Appendix A156	^1H NMR (500 MHz, CDCl_3) spectrum of compound 192d
Appendix A157	^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 192d
Appendix A158	HRESIMS (+ESI) $[\text{M}+\text{H}]^+$ for Compound 192e
Appendix A159	FTIR spectrum of compound 192e

Appendix A160	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 192e
Appendix A161	¹³ C NMR (125 MHz, CDCl ₃) spectrum of compound 192e
Appendix A162	HRESIMS (+ESI) [M+H] ⁺ for Compound 192f
Appendix A163	FTIR spectrum of compound 192f
Appendix A164	¹ H NMR (500 MHz, CDCl ₃) spectrum of compound 192f
Appendix A165	¹³ C NMR (125 MHz, CDCl ₃) spectrum of compound 192f
Appendix A166	3D and 2D binding modes of 186e at active site of α -amylase
Appendix A167	3D and 2D binding modes of 186f at active site of α -amylase
Appendix A168	3D and 2D binding modes of 187e at active site of α -amylase
Appendix A169	3D and 2D binding modes of 188b at active site of α -amylase
Appendix A170	3D and 2D binding modes of 192c at active site of α -amylase
Appendix A171	3D and 2D binding modes of 192d at active site of α -amylase
Appendix A172	3D and 2D binding modes of 192e at active site of α -amylase
Appendix A173	3D and 2D binding modes of 192e at active site of α -amylase

**SINTESIS ANALOG KARBOKSAMIDOSTILBENA MELALUI TINDAK
BALAS GANDINGAN SILANG HECK, PENILAIAN *IN SILICO* DAN
ANTIDIABETIK**

ABSTRAK

Satu siri baru sebatian terbitan *orto*-karboksamidostilbena dan *para*-karboksamidostilbena telah disintesis melalui tindak balas gandingan Heck. Struktur sebatian yang disintesis telah disahkan oleh pelbagai analisis spektroskopi, termasuk FTIR, HRESIMS, 1D-NMR (¹H NMR dan ¹³C NMR) serta 2D-NMR (COSY dan HMBC). Karboksamidostilbena telah disintesis dengan tindak balas iodofenilasilamida dalam DMF kering bersama stirena dan Et₃N sebagai bes dengan kehadiran paladium(II) asetat (Pd(OAc)₂). Kesemua karboksamidostilbena telah disaring secara *in vitro* untuk sifat perencatan α -amilase menggunakan resveratrol dan acarbose sebagai drug rujukan. Sebatian-sebatian ini menunjukkan aktiviti perencatan dari sederhana hingga baik, dengan nilai IC₅₀ berjulat antara 13.3 dan 28.2 μ M, berbanding drug rujukan resveratrol dan acarbose (masing-masing, IC₅₀ = 35.0 \pm 3.5, 30.2 \pm 0.1 μ M). Antaranya, sebatian **186e**, **186f**, **187e**, **191d**, **191e**, **191f**, **192c**, **192d**, **192e** dan **192f** menunjukkan aktiviti perencatan α -amilase yang ketara, dengan nilai IC₅₀ antara 15 hingga 38 μ M. Analisis hubungan struktur-aktiviti (SAR) telah dijalankan untuk memastikan hubungan antara struktur kimia dan aktiviti perencatan α -amilase. Penedokan molekul *in siliko* digunakan untuk menunjukkan interaksi pengikatan *orto*- dan *para*-karboksamidostilbena dengan α -amilase. Sifat farmakokinetik (ADME) dan keserupaan drug turut dikaji. Kajian penedokan molekul menunjukkan interaksi yang kuat antara molekul yang dikaji dengan pengikat α -amilase. Dapatan tenaga pengikat adalah berjulat dari -8.3 hingga -9.1 kcal/mol, berbanding akarbose, yang menunjukkan -7.8 kcal/mol. Hasil ramalan keserupaan drug menunjukkan bahawa sebatian-sebatian yang

disintesis mengikut aturan lima Lipinski, mencadangkan potensinya sebagai molekul seperti drug. Tambahan pula, penilaian sifat ADME menunjukkan profil penyerapan optimum, terutamanya berkenaan dengan penyerapan usus manusia (HIA). Sebatian **186e**, **191f**, **192f** dan **192e** menunjukkan potensi aktiviti perencatan yang paling tinggi dan interaksi yang signifikan dengan poket pengikat α -amilase, dengan nilai IC_{50} berjulat antara 13.3 hingga 21.2 μ M. Dapatan ini, berserta sifat farmakokinetik, keserupaan drug dan profil pengedokan molekul yang baik, menunjukkan potensi sebatian-sebatian ini berpotensi sebagai agen terapeutik yang berkesan dalam menguruskan diabetes.

**SYNTHESIS OF CARBOXAMIDOSTILBENE ANALOGUES VIA HECK-
CROSS COUPLING REACTION, *IN SILICO* AND ANTIDIABETES
EVALUATION**

ABSTRACT

A new series of *ortho*-carboxamidostilbene and *para*-carboxamidostilbene derivatives were synthesised via the Heck coupling reaction. The structures of the synthesised compounds were confirmed by various spectroscopic analyses, including FTIR, HRESIMS, 1D-NMR (¹H NMR and ¹³C NMR), 2D-NMR (COSY and HMBC). Carboxamidostilbenes were synthesised by reacting iodophenyl acylamide in dry DMF with styrene and Et₃N as the base in the presence of palladium (II) acetate (Pd(OAc)₂). All carboxamidostilbenes were screened *in vitro* for their α -amylase inhibition properties, using resveratrol and acarbose as referenced drugs. The compounds exhibited moderate to good inhibitory activity, with IC₅₀ values ranging from 13.3 to 28.2 μ M, compared to resveratrol and acarbose (IC₅₀ = 35.0 \pm 3.5, 30.2 \pm 0.1 μ M, respectively). Among them, compounds **186e**, **186f**, **187e**, **191d**, **191e**, **191f**, **192c**, **192d**, **192e** and **192f** showed significant α -amylase inhibitory activity, with IC₅₀ values between 13.3 and 27.9 μ M. Structure-activity relationship (SAR) analysis was performed to establish the relationship between chemical structure and α -amylase inhibitory activity. *In silico* molecular docking was used to model the binding interactions of the *ortho*- and *para*-carboxamidostilbenes with α -amylase. Pharmacokinetic properties (ADME) and drug-likeness were also investigated. Molecular docking studies showed strong interactions between the investigated molecules and the α -amylase binding pocket. The binding energy results ranged from -8.3 to -9.1 kcal/mol, compared to that of acarbose, which is -7.8 kcal/mol. The drug-likeness prediction indicated that the synthesised compounds followed Lipinski's rule

of five, suggesting their potential as drug-like molecules. Additionally, the evaluation of ADME properties demonstrated optimal absorption profiles, particularly with respect to human intestinal absorption (HIA). Compounds **186e**, **191f**, **192f**, and **192e** showed the most promising inhibitory activity and significant interactions with the α -amylase binding pocket, with IC_{50} values ranging from 13.3 to 21.2 μ M. These results, in conjunction with favourable pharmacokinetic properties, drug-likeness, and molecular docking profiles, suggested the potential of these compounds as effective therapeutic agents in managing diabetes.

CHAPTER 1

INTRODUCTION

1.1 Background of the study

In medicinal chemistry, the selection of a suitable "drug-like" scaffold serves as the first step in the development of a structure tailored to specific molecular targets (Hann *et al.*, 2001; Lipinski, 2004). For many years, the chemical peculiarity of stilbene structure has been a source of inspiration to scientists from various fields, including chemistry, biology, pharmacy, and medicine (Dewick, 2009; Madsen & Clausen, 2011). The study of polyphenols, an important group of secondary metabolites that are abundant in plants and plant foods such as grapes, berries, and nuts, is a major focus of research (Kumar & Goel, 2019; Shahidi & Ambigaipalan, 2022; Rodríguez-Gutiérrez *et al.*, 2024). Stilbenes exhibit a non-uniform distribution across different plant species with excellent photophysical and photochemical properties (Ams & Wilcos, 2007; Abbey *et al.*, 2013). Therefore, stilbene derivatives have been identified in 275 species from 105 genera and 55 families. To date, a total of 1038 stilbene derivatives have been documented, mainly distributed in 11 families, namely Stemonaceae, Dipterocarpaceae, Polygonaceae, Euphorbiaceae, Gnetaceae, Orchidaceae, Cyperaceae, Moraceae, Asparagaceae, Vitaceae and Leguminosae, accounting for 84% of the total stilbene distribution, with fewer occurrences reported in other families (More & Singh, 2015; Teka *et al.*, 2022; Xin *et al.*, 2022). Extensive research has focused on the functions of stilbenes, investigating their efficacy as antibacterial agents, antioxidants, anti-inflammatory agents, anticancer agents, and cancer prevention agents, and more recently their involvement in the regulation of various degenerative diseases in humans (Ghazarian *et al.*, 2011; Kumar *et al.*, 2011).

Drug design is an inventive approach that aims to develop new biologically active substances that match the shape and charge of their biological targets so that they can interact and bind effectively to achieve the desired biological effects (Zhou & Zhong, 2017). Stilbene, a structural motif known for its diverse pharmacological activities, serve as a scaffold for these endeavors. They consist two phenyl rings connected by an olefinic bridge, often present in two isomers *trans*-stilbene (**1**) and *cis*-stilbene (**2**) with a planar shape (Mohd Fadzli, 2016). Different conformations exhibit unique properties, exemplified in stilbenes by the remarkable variance in melting points. Studies have shown that the *trans* isomer has higher stability due to steric considerations (Latva-Mäenpää *et al.*, 2021). In contrast, the *cis*-stilbene (**2**), which is sterically hindered, exhibits lower stability, as evidenced by its lower melting point of 6°C. The *trans*-stilbene (**1**), which is more stable, has a significantly higher melting point of around 125 °C (Likhtenshtein, 2000).




Figure 1.1 Structure of *trans*- and *cis*-stilbenes

The stilbenes are synthesised in response to UV radiation, toxins, and infections. Stilbenes comprise various subclasses, including oligostilbenes, substituted *trans*-stilbene (**3**), substituted *cis*-stilbene (**4**). Stilbenoids, on the other hand, are hydroxylated forms of stilbenes derived from resveratrol (**5**) (*E*)-5-(4-hydroxystyryl)benzene-1,3-diol (Kluska *et al.*, 2023).




Figure 1.2 Structures of substituted stilbenes and resveratrol

Stilbene derivatives are naturally present in various plant species, while others are synthetically produced (Kluska *et al.*, 2023). It has been reported that the derivatives of stilbene such as diethylstilbestrol (**6**), diethylstilbestrol dipropionate (**7**), 4,4'-diaminostilbene (**8**) and 5-[(1*E*)-2-phenylethen-1-yl]benzene-1,3-diol (**9**) have shown impressive pharmacological effects in the treatment of hypocholesterolaemia, sympathomimetic, antifungal, antiallergic, antibacterial, antimalarial, and anticancer properties (Kluska *et al.*, 2023; Navarro-Orcajada *et al.*, 2022).




Figure 1.3 Chemical structures of various (*E*)-stilbene derivatives

Besides, other stilbenoids including pterostilbene (**10**) (*trans*-3,5-dimethoxy-4-hydroxytoluene), piceatannol (**11**) (*trans*-3,3',4',5-tetrahydroxystilbene), exhibit a range of biological activities, such as antioxidant, anti-inflammatory, and potential anticancer effects (Piotrowska *et al.*, 2012; Hsieh *et al.*, 2013).




Figure 1.4 Chemical structures of *trans*-3,5-dimethoxy-4-hydroxytoluene and *trans*-3,3',4,5-tetrahydroxystilbene

Stilbenoids can occur in both oligomeric and monomeric form. They can also be present as conjugated glucosides or as free phenol derivatives, also known as aglycones (Kumar *et al.*, 2011). Based on their chemical structure, stilbenoids can be categorised into five main groups: simple stilbenes, prenylated and geranylated stilbenes, 2-phenyl-benzofuran derivatives, carbon-substituted stilbenes that do not belong to the group of prenylated and geranylated stilbenes, and various other structures. Examples include puwhuskin A (**12**), rumexoid (**13**) (antidiabetic activity), ω -viniferin (**14**) (antiangiogenic) and latifolol (**15**) (anti-inflammatory) (Mattio *et al.*, 2020).




Figure 1.5 Chemical structures of notable polyphenolic compounds

The synthesis of stilbene derivatives is aimed to modify the mode of action of drugs, to minimise side effects while increasing efficacy (Singh *et al.*, 2022; Goda *et al.*, 2023). Therefore, their potential applications have been evaluated either as herbal supplements or as active ingredients in medicinal and cosmetic preparations (Kasiotis *et al.*, 2013). Consequently, one of the best-known palladium-catalysed processes for the chemical synthesis of methoxylated stilbenes is the Mizoroki-Heck reaction, often referred to as the arylation of olefins (Mino *et al.*, 2012).

As part of our ongoing research, we plan to synthesise a series of carboxamidostilbene derivatives using the Heck coupling reaction, as described by Kee *et al.* (2010); Azmi *et al.* (2013); Mohammad *et al.* (2021). This reaction is a simple and efficient method for the synthesis of carboxamidostilbene compounds. This will involve combining styrene with different iodocarboxamido compounds, which will be our starting materials. The Heck coupling reaction is known for its ability to form carbon-carbon bonds in just one step, allowing us to efficiently produce these derivatives. By using this approach, our goal is to develop a wide range of *ortho*- and *para*-carboxamidostilbene derivatives, which we will then use to evaluate for their potential biological activities and therapeutic applications. The ultimate goal is to contribute to the development of novel therapeutic agents for the treatment of diabetes through the synthesis and characterisation of innovative carboxamidostilbene derivatives (Su *et al.*, 2022).

1.2 Problem statement

The rising global prevalence of diabetes, a chronic metabolic disorder characterised by elevated blood glucose levels that cause severe damage to the heart, blood vessels, eyes, kidneys, and nerves (Rendi *et al.*, 2021), remains a significant public health challenge in Malaysia and across Asia. This underscores the urgent need for novel and effective therapeutic agents. Each year, an estimated 29.1 million individuals are affected by this condition. According to the National Health and Morbidity Survey (NHMS) conducted by the Ministry of Health Malaysia, the prevalence of diabetes increased from 11.6% in 2006 to 17.5% in 2019 (Ministry of Health Malaysia, 2019). This means that approximately 3.9 million Malaysians are currently living with diabetes (Ministry of Health Malaysia, 2019). Furthermore, the World Health Organization (WHO) predicts that diabetes will become a leading cause of death by 2030, with the death rate expected to double from 2005 to 2030 (Das *et al.*, 2018). Despite advancements in antidiabetic medications, many existing treatments have limitations, such as adverse side effects, limited efficacy, and drug resistance. Therefore, there is a critical need to develop new compounds with improved safety profiles and therapeutic efficacy.

The rational design of carboxamidostilbene derivatives as antidiabetic agents is driven by the need for effective, safe, and multi-functional drugs. Their ability to interact with key metabolic targets, improve insulin sensitivity, and mitigate oxidative stress makes them promising candidates for further development in diabetes management, particularly in Malaysia and Asia, where diabetes prevalence continues to rise.




Figure 1.6 Diabetes around the world in 2021

Olefins play a crucial role as essential structural components in natural products, pharmaceuticals, bioactive compounds, and organic materials (Shaikh & Hong, 2013). Olefinic compounds are recognised as a significant metabolically active polyphenol that is currently the focus of research interest as a potential agent to combat insulin resistance (IR) (Shazmeen *et al.*, 2021). As these metabolised polyphenols serve as bioavailable end products of metabolism, it is therefore crucial to develop analytical methods to assess the potential effects of these compounds.

1.3 Research objectives

1. To synthesise and characterise new series of *ortho*-carboxamido and *para*-carboxamidostilbene derivatives.
2. To evaluate the inhibitory effects of carboxamidostilbenes on the activities of the α -amylase enzyme.

3. To evaluate the *in silico* drug-like properties, ADME and molecular docking of the active compounds.

1.4 Scope of research

Carboxamidostilbene derivatives were synthesised via Heck coupling, with the methoxy group strategically positioned at the 3,4,5-, 2,4- and 2,5-positions of the aromatic rings. The chemical structures of these synthesised compounds were thoroughly characterised using FTIR, HRESIMS and 1D- and 2D-NMR spectroscopy.

In vitro evaluation on α -amylase enzyme performed at the School of Industrial Technology, Universiti Sains Malaysia, to evaluate the antidiabetic potential of the synthesised compounds. The α -amylase inhibition data were determined in triplicate ($n = 3$) and expressed as half maximum inhibitory concentration (IC_{50}), allowing quantitative comparison with the reference compound acarbose. In addition, *in silico* molecular docking screening, drug-likeness assessments and analysis of ADME properties (absorption, distribution, metabolism and excretion) were performed at the School of Chemical Sciences using the required software tools.

CHAPTER 2

LITERATURE REVIEW

2.1 Stilbene and its derivatives

Stilbene and its derivatives are categorised as biologically active compounds. Certain derivatives occur naturally in various plant species, while others are produced by synthetic methods (Kluska *et al.*, 2023). The structure of stilbene molecule was first elucidated by A. Laurent in 1829, marking a significant advancement in the field of organic chemistry (Kapoor, 1969). His pioneering work laid the groundwork for understanding aromatic compounds and their behaviour, which has continued to influence the synthesis and applications of stilbene derivatives in modern research. Laurent's elucidation demonstrated the potential of molecular structure analysis, emphasizing the importance of selectivity and functional group tolerance in both synthetic and natural systems (Jensen, 2008). Subsequently, numerous stilbene derivatives were synthesised, of which certain compounds exhibited different activities. For many years, the stilbene scaffold has been recognised as an outstanding structure with significant biological potential (Pecyna *et al.*, 2020). Therefore, compounds based on the stilbene scaffold, whether natural or synthetic, have shown a wide range of biological activities, including anticancer (De Filippis *et al.*, 2017), antifungal (De Filippis *et al.*, 2019), antimicrobial (Singh *et al.*, 2019), anti-inflammatory (Dvorakova & Landa, 2017) and neuroprotective (Chen *et al.*, 2017) properties. They are also promising potential agents for the treatment of diabetes (Chou *et al.*, 2018) and obesity (Li *et al.*, 2006).

This popularity has led scientists to synthesise resveratrol and its analogues to test their bioactivity. Resveratrol (**5**) indeed has a low bioavailability as it is metabolised in the liver by sulphation and glucuronidation. The bioavailability can be increase by

the development of resveratrol analogues, which would reduce the activity of the hydroxyl group of resveratrol (Baur & Sinclair 2006). Methoxylation of the hydroxyl groups should prevent the metabolism of polyphenols and increase the bioactivity of stilbenes. Methoxylated analogues of resveratrol have an increased lipophilicity, which would increase their bioavailability as they remain in the body longer instead of being excreted from the body (Zeka *et al.*, 2018). Methoxylated analogues of resveratrol such as *trans* 3,4,5,4'-tetramethoxystilbene (DMU 212) (**16**) were synthesised by the Wittig reaction. Other analogues are synthesised by the Horner-Wittig reaction, such as 2,4,4'-trimethoxystilbene (**17**) and 3,4',5-trimethoxystilbene (**18**). The mechanism of the Horner-Wittig reaction is like that of the Wittig reaction, it is a modification developed by Leopold Horner. The only difference is that the Horner-Wittig reaction selectively generates the *trans* formation of stilbene, while the Wittig reaction generates both *trans* and *cis* products (Zeka *et al.*, 2018).




Figure 2.1 Structures of methoxylated stilbene derivatives

2.2 Synthesis of stilbene and its derivatives

Numerous synthetic routes to stilbene derivatives are known, especially those used in total synthesis. The key step in the construction of the stilbene backbone is the formation of the carbon-carbon double bond (Giacomini *et al.*, 2016). Stilbene derivatives can be synthesised by using two techniques:

1. Palladium catalysed synthesis.
2. Non palladium catalysed synthesis.

2.2.1 Palladium catalysed synthesis of stilbenes


Palladium-catalysed synthesis of stilbenes is a prominent method in organic chemistry, particularly for the formation of carbon-carbon double bonds. The palladium-catalysed reactions, such as the Heck reaction and Suzuki coupling, are widely utilized for their efficiency and selectivity in synthesising these compounds (Jagtap, 2017). In these reactions, palladium acts as a catalyst to facilitate the coupling of aryl halides with alkenes or organoboron, forming the stilbene framework. The process typically occurs under mild conditions and offers a high degree of functional group tolerance, making it versatile for various stilbene derivatives (Gligorijevic *et al.*, 2021). There are a variety of reported synthetic routes to stilbene derivatives. However, in this project, the most crucial techniques that have been used in total synthesis were considered:

2.2.1(a) Heck coupling reaction

The Heck reaction, also known as the Mizoroki-Heck reaction, is a widely recognised technique for catalysing the reaction of aryl halides with alkenes to form a substituted alkene (Xue & Lin, 2010; Ruiz-Castillo & Buchwald, 2016; Roy & Uozumi, 2018; Yang *et al.*, 2018). This method, facilitated by palladium, is known for its exceptional chemo-selectivity and adaptability to a wide range of functional group

(Surry & Buchwald, 2008; Yang *et al.*, 2018). As a result, it has become an important part of modern organic synthesis and was praised for its efficiency and versatility (Karine *et al.*, 2004). Since their discovery in the early 1970s, palladium-catalysed cross-coupling reactions have been extensively studied (Xue & Lin 2010; Ruiz & Buchwald 2016; Roy & Uozumi, 2018; Biffis *et al.*, 2018; Christoffel & Ward 2018; Gonzalez-sebastian & Morales-Morales, 2019). In the course of their development, these reactions have evolved into new and improved methods for the selective coupling of carbon atoms, not only with other carbon atoms, but also with heteroatoms such as nitrogen, oxygen, and phosphorus (Astruc, 2011).


The importance of these reactions was recognised in 2010 when Richard Heck, Ei-ichi Negishi and Akira Suzuki were awarded the Nobel Prize in Chemistry for their fundamental work, which has paved the way for numerous invaluable processes used daily in both academic research and industry (Astruc, 2011). The most common palladium-catalysed cross-coupling reactions using palladium(0) as the catalytic species include the Heck reactions, Stille, Suzuki and Sonogashira (Scheme 2.1) (Nicolaou *et al.*, 2005).




Scheme 2.1 Schematic representation of palladium catalysed synthesis of stilbenes

Mizoroki–Heck coupling reactions under microwave irradiation were performed with a colloidal Pd nano catalyst stabilised with polyvinylpyrrolidone (Gonzalez & Morale, 2019). Using this method, numerous stilbenes (**21-32** shown in the scheme below) and innovative heterostilbenes were successfully produced in good to excellent yields using aryl bromides (**19**) and various olefins (**20a-c**) as starting

materials (García *et al*, 2017). The reaction was distinguished by short reaction times and low catalyst loading, leading to high turnover frequencies (TOFs). The protocol offers advantages such as simplicity of operation, high robustness, efficiency, and conversion frequency (García *et al*, 2017). The use of aqueous media and the straightforward product work-up increase the attractiveness of this approach for stilbene syntheses by the Mizoroki–Heck reaction (García *et al*, 2017).




19: X = Br, R₁ = 4-COMe (**19a**); X = Br, R₁ = 4-COPh (**19b**); X = Br, C₆H₄R₁ = 3-quinoline (**19c**); X = Br, R₁ = 3,5-diOMe (**19d**); X = Br, R₁ = 4-OMe (**19e**); X = Br, R₁ = 4-Me (**19f**); X = Br, R₁ = 2-Me (**19g**); X = I, R₁ = 4-OH (**19h**)




Scheme 2.2 Mizoroki-Heck reaction of aryl halides with olefins catalysed by PVP-Pd NPs (García *et al*, 2017)

Reddy *et al.* successfully synthesised nitrovinyl stilbenes **35** using a Mizoroki-Heck coupling reaction. The synthesis began with intermediate **33**, which was converted into stilbene **34** through a palladium-catalysed Mizoroki–Heck reaction with styrene, achieving yields ranging from 84% to 97%. Subsequently, compound **34** reacted with nitromethane to produce nitrovinyl stilbenes **35**, with yields of 79% to 96%, as illustrated in Scheme 2.3. (Reddy *et al.*, 2011).




Scheme 2.3 Synthesis of nitrovinyl stilbenes **35**

Similarly, Camp and his co-workers have developed a novel method for the *in situ* formation of palladium nanoparticles. They have also successfully optimised a base-free Mizoroki-Heck cross-coupling method for the synthesis of substituted stilbenes **38** (Bousfield, 2020). In this innovative approach, glucose plays a dual role of stabilising the palladium (0) nanoparticles, and regenerating the active catalyst species. In contrast to conventional protocols, this method does not require the use of a base, resulting in an acidic reaction mixture. It departs from traditional Mizoroki-Heck reactions, where typically alkene substrates react with aryl or alkyl halides to form C-C bonds (Bousfield, 2020). The dehydrating approach was chosen to generate styrene *in situ*, and allow a tandem cross-coupling reaction in a base-free H₂O/MeCN solvent system. This method utilises the acidic conditions of the reaction mixture. After optimisation, the steric, electronic, and substrate-specific possibilities of the reaction were thoroughly investigated. The molar efficiency (mol. E%) was calculated and compared with those obtained from similar methods for the synthesis of substituted stilbenes **38** (Bousfield, 2020).




Scheme 2.4 Base-free Mizoroki-Heck cross-coupling for the synthesis of substituted stilbene

In 2024, Guangfa *et al.* conducted a study on the synthesis of styrene **39** and stilbenes **42** using Pd-catalysed vinylation reactions of aryl iodides **40** with 1,2-dibromoethane (**41**). In these reactions, 1,2-dibromoethane (**41**) generates vinyl bromide, which then undergoes reductive cross-coupling with aryl iodides **40** to generate styrene products **39**. By slightly changing the reaction conditions, the styrene **39** can further react with vinyl bromide to form *E*-stilbenes, which is a convenient one-pot method for the synthesis of stilbenes **42**. In the reductive cross-coupling reactions, alcohols such as isopropanol and methanol are used as reducing agents (Guangfa *et al.* 2024).




Scheme 2.5 A recent one-pot synthesis of stilbene using Heck reaction with solvent modification

Tuanli *et al.* reported a novel palladium-catalysed multicomponent reaction involving olefin-linked aryl iodides **43**, aryls **44** and electrophilic alkenes **45**. This innovative approach enables the direct synthesis of *o*-alkylated aryl acrylates and stilbenes **46** by an intramolecular tandem process involving Heck cyclisation and dicarbofunctionalisation of the aryne (Tuanli *et al.*, 2021).



Scheme 2.6 Synthesis of stilbene scaffold


In 2013, Azmi *et al.*, synthesised nineteen *o*-carboxamidostilbenes **49** by Heck coupling by reacting 2-iodoamide **48** with styrene **47**. These compounds had various substituted groups linked to the amide group on ring A, as well as electron-withdrawing groups (Cl, Br and F) and electron-donating groups (methoxy) at different positions on ring B. Among these, three compounds showed remarkable cytotoxicity against three cancer cell lines: Colon cancer, prostate cancer, and breast cancer, with IC₅₀ values of 7.51 μM, 16.68 μM and 21.24 μM, respectively (Azmi *et al.*, 2013).



Scheme 2.7 Heck reaction of *N*-(2-iodophenyl)acetylamine with styrene

The decarbonylative Heck reaction is a frequently used method to produce resveratrol (**5**) and its derivatives **52**. This variant of the Heck reaction has been known since the early 1980s. The pioneering work of Spencer *et al.* demonstrated the palladium-catalysed coupling of alkenes to aroyl chlorides **50** in the presence of a tertiary amine (Spencer, 1983; Moran *et al.*, 2009). Spencer also described the arylation of ethylene leading to the formation of styrene and stilbene derivatives **52**. This reaction involves the efficient decarbonylation of the aroyl chloride **50**. It is not particularly

influenced by substituents on the aryl chloride **50**, although strongly electron-donating groups have been shown to be favourable (Moran *et al.*, 2009). Furthermore, when monosubstituted alkenes **51** are used, the *trans* isomer is formed with complete specificity (Spencer, 1983).




Scheme 2.8 Decarbonylative Heck reaction

The decarbonylative Heck reaction shows optimal performance when tertiary bases with pKa values between 7.5 and 11 are used. It was observed that weaker bases resulted in slower reaction rates, while stronger bases interacted undesirably with the aryl chloride **50**, leading to side reactions or reduced efficacy (Spencer, 1983). *N*-ethyl morpholine emerged as the most effective base because it did not react with aryl chlorides **50** and maintained the integrity of bonds between the aryl chloride **50** and strong electron-withdrawing groups. To optimise the reaction, *p*-xylene was used as the solvent, and the reaction temperature was maintained between 120 and 130 °C, which produced the most favourable outcomes (Spencer, 1983).

In 2012, Paul John Joseph Colbon developed a two-step one-pot reaction. First, the secondary aryl alcohol **53** was dehydrated in the presence of heteropoly acid (HPA) to facilitate the reaction. A mixture of secondary aryl alcohol **53** and HPA in DMSO was stirred at 100°C for 1 hour. A mixture containing aryl bromide, Et₃N, Pd(*dba*)₂ and P(*t*-Bu)₃.HBF₄ in DMF was then added and the resulting mixture was stirred for a further 4 hours, leading to the efficient formation of the desired stilbene product **55** with


an isolated yield of 82%. The reaction cascade was performed in a sequential manner, exhibiting noteworthy tolerance towards various functionalities that are present on the aryl bromide. As a result, functionalised stilbenes were obtained in favourable yields. Notably, both electron-rich and electron-poor aryl bromides were effectively utilised, with substitutions at the *ortho*-, *meta*-, and *para*-positions presenting no significant hindrance. The demonstrated versatility underscores the robust nature of this method, making it highly suitable for the synthesis of a wide range of stilbene derivatives **55** (Colbon, 2012).



Scheme 2.9 Dehydration Heck arylation of benzylic alcohol **55** with aryl bromides

Song and colleagues have successfully performed the first total synthesis of gaylussacin (**61a**), pinosylvikinic acid (**60a**) and novel stilbene derivatives **61b** and **60b** (Song *et al.*, 2021). An important intermediate **56**, was synthesised in three steps by selective protection and functionalisation of commercially available 2,4,6-trihydroxybenzoic acid. The stilbene segment was efficiently constructed via the Heck reaction while simultaneously removing the benzoyl group. Gaylussacin **61a** and **61b**


were obtained with an overall yield of 23.8% and 15.9%, respectively. In addition, pinosylvinic acid (**60a**) and resveratronic acid (**60b**) were synthesised via a modified route with an overall yield of 25.3% and 26.4%, respectively (Song *et al.*, 2021). Furthermore, the developed synthetic route was utilised to produce a phthalide compound. This investigation provides a concise and effective synthetic pathway for 2-carboxyl stilbene compounds, which is important for the future design and synthesis of stilbene glycoside derivatives (Song *et al.*, 2021).



Scheme 2.10 Synthesis of Gaylussacin (**61a**) and its derivative (**61b**)

Recently, Sian conducted research in which forty (40) 1,3-diarylpropene derivatives **65-68** were synthesised and reported. These analogues were designed based on stilbenoids and dihydrostilbenoids which were synthesised using palladium-catalysed reactions with 2-amidoiodobenzene derivatives **62** and either estragole (**63**) or eugenol (**64**). The products showed high (*E*)-stereoselectivity but were present as two


regioisomers. The ratio of these isomers was found to be dependent on the nature of the allylbenzene partner, with electronic effects playing a crucial role in the β -hydride elimination step. In addition, the cytotoxic effects of all Heck reaction products were investigated against human breast cancer cell lines. Compound **65i** showed mild cytotoxic activity against MCF-7 cell lines with IC_{50} values of 47.92 μ M compared to tamoxifen (Tan, 2022).



Scheme 2.11 Synthesis of amido 1,3-diarylpropene compounds

Lerch *et al.* reported a study in which imidazolium-based tunable arylalkyl-ionic liquids (TAAILs) were used as solvents in the Mizoroki–Heck reaction. Thus, commercially available palladium (II) acetate (Pd(OAc)_2), inorganic bases (K_2CO_3), TAAILs and reaction conditions were investigated for the synthesis of *trans*-stilbene from bromobenzene and styrene (Lerch *et al.*, 2022). They successfully synthesised a series of stilbene derivatives yielding exclusively (*E*)-isomers **69** with isolated yields of up to 97%. Optimisation of the reaction conditions showed that the use of only 0.25 mol% Pd(OAc)_2 as a catalyst with a reaction time of 4 hours gave the best results. No additional ligands or additives was required. The catalytic system using TAAILs showed higher yields compared to commercially available imidazolium and

phosphonium ionic liquids, highlighting the potential of customised ionic liquids as a reaction medium for the Mizoroki–Heck reaction. The electronic properties of TAAILs can be customised by changing the substitution on the aryl moiety, and varying the length of the alkyl group (Ahrens *et al.*, 2009). The usefulness of TAAILs as a reaction medium for the palladium-catalysed Mizoroki–Heck reaction with various aryl bromides **19a** and styrene derivatives **40** has been successfully demonstrated (Lerch *et al.*, 2022).




Scheme 2.12 Synthesis of stilbene utilising TAAILs in the Mizoroki–Heck reaction

2.2.1(b) Stille coupling reaction

Among the various Pd-catalysed cross-coupling reactions, the Stille reaction is one of the most efficient and selective methods for building carbon-carbon bonds in organic synthesis. The palladium-catalysed coupling of organotin reagents with organic electrophiles, such as aryl and vinyl halides or triflates, is referred to as the Stille reaction (Yoshiaki *et al.*, 1996). Unlike the Suzuki coupling, the Stille reaction does not need a base to be added and is applicable to a broader range of electrophiles, including saturated aliphatic halides and certain alcohol derivatives. While organostannanes are highly valuable synthetic intermediates due to their compatibility with most functional groups and under mild conditions (Yoshiaki *et al.*, 1996).

Organic tellurides (**67**) showed more efficient reactivity with a range of alkenes in the presence of Pd(II) salts, yielding the corresponding substituted stilbenes **68**. Initially, the reaction was performed using a stoichiometric amount of palladium acetate or palladium chloride alongside triethylamine, but it became catalytic when an oxidant, such as silver acetate, was introduced into the system (Scheme 2.13) (Yoshiaki *et al.*, 1996).




Scheme 2.13 Synthesis of substituted stilbenes via the Stille coupling reaction

2.2.1(c) Suzuki coupling reaction

The Suzuki coupling reaction is frequently used in stilbene synthesis, as it enables efficient production of arylboronic acids or borates from trialkyl borates using Grignard or organolithium reagents. This method is well suited for both industrial production and laboratory scale applications (Wu *et al.*, 2010). In a recent study, the incorporation of the *t*-Bu₃PHBF₄ ligand into the Suzuki reaction was found to increase the stereoselectivity of (*E*)-stilbene formation. In addition, it improved the adaptability to a wide range of substrates, both electronically and sterically (Rau & Werner, 2018). The pinacol boronic acid ester (**69**), when coupled with aryl bromide **70-84**, gave (*E*)-stilbene analogues **85-96** with yields between 44% and 76% (Scheme 2.14) (Rau & Werner, 2018).

However, in contrast to Negishi coupling, Suzuki coupling is not the favoured method in the synthesis of stilbene scaffold **85-96**. This is due to several factors, including the complexity of the reactants, preparation of the organometallic reagents, time efficiency and performance of the synthesis yield, as briefly mentioned above in

the references (Rau & Werner, 2018). Instead of using organometallic reagents, two alternative methods using alkenes and alkynes, namely Sonogashira and Heck coupling reactions, are considered here.



Scheme 2.14 The Suzuki cross-coupling synthesis of stilbene scaffold

Besides, Heck coupling reactions involving aryldiazonium salts or organic halides as electrophiles, the utilisation of nucleophilic organoboron species has emerged as a subject of considerable interest for synthesising stilbene derivatives. The Suzuki reaction, a palladium-catalysed cross-coupling reaction between boranes or boronic acids and esters with organic halides or diazonium salts, has proven to be highly selective and compatible with a wide range of functional groups present on either coupling reagent. Moreover, the reagents employed in this reaction are easily prepared and generally exhibit robustness in the presence of water (Eddarir *et al.*, 2001).

The Suzuki coupling reaction between 1,1-bromofluorostyrene and phenylboronic acid is commonly utilised as a versatile method for the synthesis of polyhydroxylated stilbenes that are monofluorinated at the central double bond (Eddarir *et al.*, 2001). Cross-couplings between aryldiazonium salts **97** and styrylboronic acid (**98**), employing a catalytic system consisting of palladium(II) acetate and an imidazolium ligand precursor, led to the formation of various stilbene derivatives **99**. These reactions were carried out under mild conditions, without the need for any additional base, and achieved high yields ranging from 68% to 87% (Scheme 2.15). It

